ASP 1004
Alternative Names: ASP-1004Latest Information Update: 22 Aug 2022
At a glance
- Originator Affinivax
- Developer Affinivax; Astellas Pharma
- Class Conjugate vaccines; Pneumococcal vaccines; Pseudomonas vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Klebsiella infections; Pseudomonal infections
Most Recent Events
- 16 Aug 2022 Affinivax has been acquired by GlaxoSmithKline
- 17 Feb 2021 Preclinical trials in Klebsiella infections (Prevention) in Japan, prior to February 2021 (Affinivax pipeline, February 2021)
- 17 Feb 2021 Preclinical trials in Klebsiella infections (Prevention) in USA, prior to February 2021 (Affinivax pipeline, February 2021)